<DOC>
	<DOC>NCT00489255</DOC>
	<brief_summary>The purposes of the study are to determine: i. To assess the efficacy of Tigan® (trimethobenzamide) in preventing nausea and vomiting when initiating therapy with Apokyn® (apomorphine) ii. To determine the optimal duration for continuation of Tigan® following initiation of Apokyn® therapy iii. To assess the safety of Tigan® in combination with Apokyn® iv. To characterize the pharmacokinetic (PK) profile of apomorphine in subjects treated concomitantly with and without Tigan®</brief_summary>
	<brief_title>Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment</brief_title>
	<detailed_description>Initial randomization is Tigan or Placebo (3:1) with phased withdrawal of Tigan to Placebo after 4 and 8 weeks. Subjects completing 4 weeks Tigan re-randomized to Tigan or Placebo (2:1) with patients completing 8 weeks Tigan re-randomized to receive Tigan or Placebo (1:1). Subjects randomized to Placebo over the previous 4 weeks assigned to continue on Placebo for the remainder of the study.</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Trimethobenzamide</mesh_term>
	<criteria>Subjects aged 18 years or over Subjects with advanced Parkinson's disease with disabling hypomobility ("off" episodes) who are to be initiated with Apokyn® by intermittent subcutaneous injection Able to swallow Tigan®/placebo capsules Subjects willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures Women of child bearing potential must have a negative serum pregnancy test (beta hCG) prior to receiving study drug and must be using an appropriate form of contraception Willing and able to provide informed consent Hypersensitive to apomorphine hydrochloride or any of the ingredients of Apokyn® (notably sodium metabisulfite) Hypersensitive to trimethobenzamide or any of the ingredients of Tigan® Previous treatment with Apokyn® Participation in any other clinical trial within 14 days of the present trial Contraindications to Apokyn® or Tigan® Currently taking, or likely to need to take at any time during the course of the study, any 5HT3 antagonist (ondansetron, alosetron, granisetron, palonosetron or dolasetron) Malignant melanoma or a history of previously treated malignant melanoma Pregnancy or breast feeding Receipt of any investigational (i.e. unapproved) medication within 30 days of starting the present trial Any significant medical disorder, condition, concomitant medication or psychiatric disorder according to DSMIV criteria which would, in the opinion of the investigator, represent a hazard to the subject or prevent the subject from completing the trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Parkinson's disease</keyword>
	<keyword>Anti-emetic</keyword>
	<keyword>Nausea</keyword>
	<keyword>Vomiting</keyword>
</DOC>